Evaluation of the risk of venous thromboembolism after quadrivalent human papillomavirus vaccination among US females

Vaccine

Volumn 34, Issue 1, 2016, Pages 172-178

  Yih, W Katherine ^a   Greene, Sharon K ^a   Zichittella, Lauren ^a   Kulldorff, Martin ^a   Baker, Meghan A ^a   de Jong, Jill L O ^b   Gil Prieto, Ruth ^a,c   Griffin, Marie R ^d   Jin, Robert ^a   Lin, Nancy D ^e   McMahill Walraven, Cheryl N ^f   Reidy, Megan ^a   Selvam, Nandini ^g   Selvan, Mano S ^h   Nguyen, Michael D ⁱ  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSIDAD REY JUAN CARLOS   (Spain)

^d VANDERBILT UNIVERSITY   (United States)

^e OPTUM   (United States)

^f Data Science Department   (United States)

^g HealthCore   (United States)

^h HUMANA INC   (United States)

ⁱ CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

HPV vaccine; Postmarketing product safety; Research design; Vaccine safety; Venous thromboembolism

Indexed keywords

CONTRACEPTIVE AGENT; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; COMPARATIVE STUDY; CONTRACEPTIVE BEHAVIOR; DISEASE ASSOCIATION; DRUG POTENCY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 4; ICD-9; MAJOR CLINICAL STUDY; MEDICAL RECORD; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK FACTOR; UNITED STATES; VACCINATION; VENOUS THROMBOEMBOLISM; CHEMICALLY INDUCED; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; INCIDENCE; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; POSTMARKETING SURVEILLANCE; RISK ASSESSMENT; YOUNG ADULT;

ADOLESCENT; CHILD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMAN PAPILLOMAVIRUS RECOMBINANT VACCINE QUADRIVALENT, TYPES 6, 11, 16, 18; HUMANS; INCIDENCE; PAPILLOMAVIRUS INFECTIONS; PRODUCT SURVEILLANCE, POSTMARKETING; RISK ASSESSMENT; UNITED STATES; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 84949725399     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.09.087     Document Type: Article

References (22)

1. Markowitz L.E., Dunne E.F., Saraiya M., et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2014, 63(RR-05):1-30.
2. Merck. Briefing document on Gardasil presented to Vaccines and Related Biological Products Advisory Committee (VRBPAC) on May 18, 2006. http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4222b-index.htm. Accessed May 12, 2015.
3. Slade B.A., Leidel L., Vellozzi C., et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009, 302(7):750-757.
4. Gee J., Naleway A., Shui I., et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine 2011, 29(46):8279-8284.
5. Boulet S.L., Grosse S.D., Thornburg C.D., Yusuf H., Tsai J., Hooper W.C. Trends in venous thromboembolism-related hospitalizations, 1994-2009. Pediatrics 2012, 130:e812-e820.
6. Nguyen M. Gardasil Post-Approval Adverse Event Review-- Pediatric Advisory Committee Meeting, December 7, 2010. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM235891.pdf. Accessed May 12, 2015.
7. Nguyen M., Ball R., Midthun K., Lieu T.A. The Food and Drug Administration's Post-Licensure Rapid Immunization Safety Monitoring program: strengthening the federal vaccine safety enterprise. Pharmacoepidemiol Drug Saf 2012, 21(Suppl 1):291-297.
8. Klein N.P., Hansen J., Chao C., et al. Safety of quadrivalent human papillomavirus vaccine administered routinely to females. Arch Pediatr Adolesc Med 2012, 166(12):1140-1148.
9. Arnheim-Dahlström L., Pasternak B., Svanstrom H., Sparen P., Hviid A. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ 2013, 347:f5906. 10.1136/bmj.f5906.
10. Scheller N.M., Pasternak B., Svanström H., Hviid A. Quadrivalent human papillomavirus vaccine and the risk of venous thromboembolism. JAMA 2014, 312(2):187-188.
11. Greene S.K., Kulldorff M., Lewis E.M., et al. Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project. Am J Epidemiol 2010, 171(2):177-188.
12. Klein N.P., Hansen J., Lewis E., et al. Post-marketing safety evaluation of a tetanus toxoid, reduced diphtheria toxoid and 3-component acellular pertussis vaccine administered to a cohort of adolescents in a United States health maintenance organization. Pediatr Infect Dis J 2010, 29(7):613-617.
13. Spencer F.A., Emery C., Lessard D., et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med 2006, 21(7):722-727.
14. Vandenbroucke J.P., Rosing J., Bloemenkamp K.W.M., et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001, 344(20):1527-1535.
15. Vlieg A.V., Helmerhorst F.M., Vandenbroucke J.P., Doggen C.J.M., Rosendaal F.R. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009, 339:b2921. 10.1136/bmj.b2921.
16. Trenor C.C., Chung R.J., Michelson A.D., et al. Hormonal contraception and thrombotic risk: a multidisciplinary approach. Pediatrics 2011, 127(2):347-357.
17. Naus J. The distribution of the size of the maximum cluster of points on a line. J Am Stat Assoc 1965, 60(310):532-538.
18. Kulldorff M. A spatial scan statistic. Commun Stat Theory Methods 1997, 26(6):1481-1496.
19. Kulldorff M and Information Management Services Inc. SaTScanTM v9.3: Software for the spatial and space-time scan statistics. 2014. http://www.satscan.org. Accessed May 12, 2015.
20. Yih W.K., Greene S.K., Zichittella L., et al. Evaluation of the risk of venous thromboembolism after Gardasil vaccination. Final report posted to Mini-Sentinel website April 2015, http://mini-sentinel.org/assessments/medical events/details.aspx?ID=123. Accessed November 23, 2015.
21. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults--the evidence report. National Institutes of Health. Obes Res 1998;6(Suppl 2):51S-209S.
22. Barlow S.E. and the Expert Committee. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics 2007, 120(Suppl 4):S164-S192.